The Lynx Group

Conference Correspondent

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

Conference Correspondent — October 22, 2018
Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early.
Read Article

Conference Correspondent — October 22, 2018
A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer.
Read Article

Conference Correspondent — October 21, 2018
Results from the phase 3 SOLO1 trial demonstrate a substantial, unprecedented improvement in progression-free survival for olaparib versus placebo.
Read Article

Conference Correspondent — October 21, 2018
Results from the KEYNOTE-100 study show that expression of PD-L1 and inflamed T-cell–associated genes are associated with clinical response in advanced, recurrent ovarian cancer.
Read Article

Conference Correspondent — October 19, 2018
Similar to the capsule formulation, olaparib tablets have no cumulative toxicity, few late-onset adverse events, and a low rate of treatment discontinuation.
Read Article

Conference Correspondent — October 19, 2018
Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens.
Read Article

Conference Correspondent — October 19, 2018
Results suggest that the combination of durvalumab and olaparib was well-tolerated and had clinical activity in heavily pretreated, BRCA-wildtype ovarian cancer patients.
Read Article

Conference Correspondent — October 19, 2018
This combination of antiangiogenic and immune checkpoint blockade has clinical activity in women with recurrent ovarian cancer.
Read Article

Conference Correspondent — October 18, 2018
Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support.
Read Article

Conference Correspondent — October 18, 2018
The novel combination of carboplatin, pegylated liposomal doxorubicin, and bevacizumab has a promising safety and efficacy profile.
Read Article

Page 10 of 41

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: